PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd.

TTSE:6190
249.00
JPY
-1.00
(-0.40%)
3.67EPS
89.82P/E
1.34BMarket Cap
Feb 12Next Earn
PhoenixBio Co., Ltd.
TSE:6190
(Tokyo Stock Exchange)

Recent

price

249.00

P/E

ratio

89.82

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
352.69
479.18
425.45
311.09
420.98
447.27
313.42
401.22
625.29
453.58
380.54
385.15
349.92
Revenue per Share
22.72
49.32
44.43
-93.36
-101.96
-141.84
-73.6
-117.5
145.23
6.98
-110.83
30.81
3.67
Basic EPS, GAAP
-6.26
94.37
12.2
-66.73
-77.13
-14.75
-87.89
2.92
78.05
-31.22
-26
13.33
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
365.92
683.94
728.38
639.26
527.82
396
332.71
250.42
416.78
446.27
337.1
381.46
359.77
Book Value per Share
365.18
683.03
726.73
512.84
429.13
395.02
331.92
249.96
415.34
443.55
332.58
377.79
356.38
Tangible Book Value per Share
2
3
3
3
3
3
3
3
3
4
4
4
4
Basic Weighted Avg Shares
881
1,217
1,229
902
1,228
1,311
1,014
1,325
2,124
1,715
1,541
1,566
1,424
Sales/Revenue/Turnover
20.81
28.15
11.57
-29.77
-25.39
-11.19
-27.32
-12.65
23.94
0.65
-9.22
5.29
-2.41
Operating Margin (%)
22
22
25
24
63
85
55
86
24
25
28
34
- -
Depreciation Expense
57
125
128
-271
-297
-416
-238
-388
493
26
-449
125
15
Net Income, GAAP
9.35
14.87
1.55
- -
- -
- -
- -
- -
3.39
55.88
- -
4.73
29.8
Effective Tax Rate (%)
6.44
10.29
10.44
-30.01
-24.22
-31.71
-23.48
-29.28
23.23
1.54
-29.13
8
1.05
Profit Margin (%)
791
1,669
1,785
1,119
831
1,722
1,401
1,415
1,006
1,711
1,151
1,270
1,163
Working Capital
137
88
116
71
43
1,077
1,010
1,008
215
491
353
267
120
LT Debt
1,057
1,975
2,104
1,857
1,543
1,162
1,094
828
1,514
1,798
1,365
1,553
1,464
Total Equity
- -
9.54
6.32
- -
- -
- -
- -
- -
21.42
0.19
- -
3.95
-1.37
Return on Invested Capital (%)
- -
7.58
5.92
- -
- -
- -
- -
- -
22
1.07
- -
6.54
1.04
Return on Capital (%)
- -
8.26
6.29
-13.67
-17.5
-30.74
-21.1
-40.37
42.12
1.59
-28.39
8.58
1.05
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
180
220
180
LT Borrowings
160
140
120
LT Finance Leases
- -
127
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
1,970
1,791
1,343

Working Capital

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
1,639
1,643
1,528
Cash, Cash Equivalents & STI
1,054
1,148
1,104
Accounts Receivable, Net
197
136
76
Inventories
321
308
298
Total Current Liabilities
388
373
364
Payables & Accruals
- -
- -
- -
ST Debt
180
220
180
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.43%
13.39%
13.71%
Free Cash Flow
200.2%
448.75%
-151.47%
Net Income, GAAP
-249.03%
-437.72%
-127.89%
Sales/Revenue/Turnover
5.78%
12.65%
1.57%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
449
339
355
398
1,541
2026
400
356
444
365
1,566
2027
259
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5.75
-36.63
-6.42
-73.61
-110.83
2026
4.74
-1.69
19.88
7.86
30.81
2027
-22.38
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Business
PhoenixBio Co., Ltd. (6190.T) develops and provides specialized contract research services for drug discovery and development, primarily utilizing its proprietary PXB-mouse, a chimeric mouse model with a highly humanized liver containing up to 90% human hepatocytes. The company offers PXB-mouse services for in vivo studies including drug metabolism and pharmacokinetics (DMPK), toxicology, viral hepatitis (HBV and HBV/HDV), nonalcoholic steatohepatitis (NASH/MASH)/NAFLD, gene-based therapeutics, oligonucleotide therapies, and custom transplantations; PXB-cells, fresh or cryopreserved human hepatocytes derived from PXB-mice for in vitro studies; and Tg & KO animal services with custom transgenic animals. It operates production and research facilities in Japan, the United States, and internationally, producing over 4,000 PXB-mice annually with consistent quality for global pharmaceutical and academic clients. Founded in 2002 and headquartered in Higashi-Hiroshima City, Japan, PhoenixBio maintains subsidiaries including PhoenixBio USA Corporation in New York and CMHL Consortium LLC in Delaware, USA, supporting project management, sales, and collaborative research consortia with pharmaceutical leaders. In February 2025, PhoenixBio entered a business partnership with TOPPAN Holdings Inc. to co-develop and commercialize artificial 3D liver tissue models combining TOPPAN's invivoid 3D cell culture technology with PhoenixBio's PXB-cells, enhancing applications in drug discovery, personalized cancer treatment, high-sensitivity liver toxicity evaluation, and translational research. The company continues active global engagement, with recent announcements for presentations on PXB-mouse and PXB-Shizuku technologies at conferences including CTRMS 2025, European Society of Gene and Cell Therapy, and ISSX 2025 in September 2025.